Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a senegalese cohort of HIV-1-exposed seronegative individuals

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Mous, Kim ^a,b   Jennes, Wim ^b   Camara, Makhtar ^c   Seydi, Moussa ^c   Daneau, Géraldine ^b   Mboup, Souleymane ^c   Kestens, Luc ^b   van Ostade, Xaveer ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c Centre Hospitalier Universitaire Dakar   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CELL PROTEIN; LENS EPITHELIUM DERIVED GROWTH FACTOR; LENS EPITHELIUM DERIVED GROWTH FACTOR P75; MESSENGER RNA; TETHERIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POPULATION EXPOSURE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTIGENS, CD; CARRIER PROTEINS; CYTIDINE DEAMINASE; ENVIRONMENTAL EXPOSURE; FEMALE; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; RNA, MESSENGER; SENEGAL; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858958569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033934     Document Type: Article

References (46)

1. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, et al. (2009) Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 5: e1000437.
2. MacPherson JI, Dickerson JE, Pinney JW, Robertson DL, (2010) Patterns of HIV-1 protein interaction identify perturbed host-cellular subsystems. PLoS Comput Biol 6: e1000863 10.1371/journal.pcbi.1000863 [doi].
3. Strebel K, Luban J, Jeang KT, (2009) Human cellular restriction factors that target HIV-1 replication. BMC Med 7: 48.
4. Cherepanov P, Maertens G, Proost P, Devreese B, Van BJ, et al. (2003) HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 278: 372-381.
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
6. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
7. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430 nature06553 [pii];10.1038/nature06553 [doi].
8. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, et al. (2005) A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 11: 1287-1289.
9. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z, (2006) Cellular co-factors of HIV-1 integration. Trends Biochem Sci 31: 98-105 S0968-0004(05)00346-4 [pii];10.1016/j.tibs.2005.12.002 [doi].
10. Zhang X, Kondo M, Chen J, Miyoshi H, Suzuki H, et al. (2010) Inhibitory effect of human TRIM5alpha on HIV-1 production. Microbes Infect 12: 768-777 S1286-4579(10)00131-0 [pii];10.1016/j.micinf.2010.05.004 [doi].
11. Black LR, Aiken C, (2010) TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol 84: 6564-6569 JVI.00210-10 [pii];10.1128/JVI.00210-10 [doi].
12. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103: 5514-5519.
13. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361-365 nature09976 [pii];10.1038/nature09976 [doi].
14. Jin X, Brooks A, Chen H, Bennett R, Reichman R, et al. (2005) APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 79: 11513-11516.
15. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, et al. (2008) Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis 198: 486-492 10.1086/590212 [doi].
16. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G, (2009) APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6: 23 1742-4690-6-23 [pii];10.1186/1742-4690-6-23 [doi].
17. Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, et al. (2006) APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol 80: 2069-2072.
18. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82: 3125-3130 JVI.01533-07 [pii];10.1128/JVI.01533-07 [doi].
19. Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, et al. (2010) APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24: 195-204 10.1097/QAD.0b013e3283353bba [doi].
20. Sewram S, Singh R, Kormuth E, Werner L, Mlisana K, et al. (2009) Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J Infect Dis 199: 1657-1663 10.1086/598861 [doi].
21. Biasin M, Piacentini L, Caputo SL, Kanari Y, Magri G, et al. (2007) Apolipoprotein B mRNA-Editing Enzyme, Catalytic Polypeptide-Like 3G: A Possible Role in the Resistance to HIV of HIV-Exposed Seronegative Individuals. J Infect Dis 195: 960-964.
22. Miyazawa M, Lopalco L, Mazzotta F, Lo CS, Veas F, et al. (2009) The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 23: 161-175 10.1097/QAD.0b013e3283196a80 [doi];00002030-200901140-00002 [pii].
23. Camara M, Dieye TN, Seydi M, Diallo AA, Fall M, et al. (2010) Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. J Infect Dis 201: 835-842 10.1086/651000 [doi].
24. Jennes W, Camara M, Dieye T, Mboup S, Kestens L, (2008) Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection. J Virol 82: 8619-8628.
25. Mous K, Jennes W, De RA, Pintelon I, Kestens L, et al. (2011) Intracellular detection of differential APOBEC3G, TRIM5alpha, and LEDGF/p75 protein expression in peripheral blood by flow cytometry. J Immunol Methods S0022-1759(11)00152-9 [pii];10.1016/j.jim.2011.06.028 [doi].
26. McLaren PJ, Ball TB, Wachihi C, Jaoko W, Kelvin DJ, et al. (2010) HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis 202 (Suppl 3): S339-S344 10.1086/655968 [doi].
27. Madlala P, Gijsbers R, Christ F, Hombrouck A, Werner L, et al. (2011) Association of Polymorphisms in the LEDGF/p75 Gene (PSIP1) with Susceptibility to HIV-1 Infection and Disease Progression. AIDS 10.1097/QAD.0b013e328349c693 [doi].
28. Marshall HM, Ronen K, Berry C, Llano M, Sutherland H, et al. (2007) Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2: e1340 10.1371/journal.pone.0001340 [doi].
29. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, et al. (2007) LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 21: 1767-1778 21/14/1767 [pii];10.1101/gad.1565107 [doi].
30. Zheng Y, Ao Z, Jayappa KD, Yao X, (2010) Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase. Virol J 7: 68 1743-422X-7-68 [pii];10.1186/1743-422X-7-68 [doi].
31. Zielske SP, Stevenson M, (2006) Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. J Virol 80: 7275-7280 80/14/7275 [pii];10.1128/JVI.02470-05 [doi].
32. Coleman CM, Spearman P, Wu L, (2011) Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 8: 26 1742-4690-8-26 [pii];10.1186/1742-4690-8-26 [doi].
33. Jolly C, Booth NJ, Neil SJ, (2010) Cell-Cell Spread of Human Immunodeficiency Virus Type 1 Overcomes Tetherin/BST-2-Mediated Restriction in T cells. J Virol 84: 12185-12199 JVI.01447-10 [pii];10.1128/JVI.01447-10 [doi].
34. Gummuluru S, Kinsey CM, Emerman M, (2000) An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 74: 10882-10891.
35. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398 S1931-3128(08)00126-1 [pii];10.1016/j.chom.2008.04.008 [doi].
36. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J, (2009) Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses 25: 1197-1210 10.1089/aid.2009.0253 [doi].
37. Chen K, Huang J, Zhang C, Huang S, Nunnari G, et al. (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 80: 7645-7657.
38. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC, (2007) Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 282: 3539-3546 M610138200 [pii];10.1074/jbc.M610138200 [doi].
39. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485 JVI.01089-09 [pii];10.1128/JVI.01089-09 [doi].
40. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, et al. (2005) A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun 338: 1950-1956 S0006-291X(05)02472-1 [pii];10.1016/j.bbrc.2005.10.173 [doi].
41. Sakuma R, Mael AA, Ikeda Y, (2007) Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol 81: 10201-10206 JVI.00419-07 [pii];10.1128/JVI.00419-07 [doi].
42. Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, et al. (2008) Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci 99: 2461-2466 CAS968 [pii];10.1111/j.1349-7006.2008.00968.x [doi].
43. Sharma P, Singh DP, Fatma N, Chylack LT Jr, Shinohara T, (2000) Activation of LEDGF gene by thermal-and oxidative-stresses. Biochem Biophys Res Commun 276: 1320-1324 10.1006/bbrc.2000.3606 [doi];S0006-291X(00)93606-4 [pii].
44. Takamura Y, Fatma N, Kubo E, Singh DP, (2006) Regulation of heavy subunit chain of gamma-glutamylcysteine synthetase by tumor necrosis factor-alpha in lens epithelial cells: role of LEDGF/p75. Am J Physiol Cell Physiol 290: C554-C566 290/2/C554 [pii];10.1152/ajpcell.00398.2005 [doi].
45. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622 clinchem.2008.112797 [pii];10.1373/clinchem.2008.112797 [doi].
46. Chiu YL, Greene WC, (2006) Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol 27: 291-297.